Skip to content
drillr.ai
Sign up

TAK

Takeda Pharmaceutical Company Limited

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP

Also listed · 4502.T →
$21.06
+1.49%
Ask drillr

  • Oct 29, 2026, 16:46 UTC

    Takeda Pharmaceutical reported second-quarter adjusted earnings of 48 cents per share, above the 31-cent consensus forecast.

    Source:

  • Oct 29, 2026, 07:36 UTC

    Takeda Pharmaceutical raised its current-year net profit forecast by 26%.

    Source:

  • Oct 29, 2026, 06:36 UTC

    Takeda announced financial results for the first half of fiscal year 2026, covering April 1 through September 30, 2026.

    Source:

  • Oct 26, 2026, 11:54 UTC

    Takeda Pharmaceutical plans to seek Japanese approval in fiscal 2027 for the gastric-cancer drug candidate arcotatug tabatacan, co-developed with Innovent Biologics, Inc., after a late-stage trial in 464 patients in Japan and China found it extended survival in patients with advanced disease.

    Source:

  • Oct 24, 2026, 23:15 UTC

    Tokyo Stock Exchange Prime Market margin short positions increased from October 9 to October 16, 2026, with Kobe Bussan leading the listed increases at 3.482 million shares.

    Source:

  • Oct 23, 2026, 11:30 UTC

    Takeda Pharmaceutical reported that its ADC drug TAVATECAN met both primary endpoints in patients with CLDN18.2-positive advanced gastric cancer.

    Source:

  • Oct 23, 2026, 10:30 UTC

    Innovent Biologics, Inc. announced positive topline Phase 3 G-HOPE-001 results for arcotatug tavatecan, reporting improved overall survival and progression-free survival versus physician’s choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction cancer.

    Source:

  • Oct 23, 2026, 02:34 UTC

    China’s National Medical Products Administration approved Takeda’s brentuximab vedotin for use with cyclophosphamide, doxorubicin and prednisone to treat previously untreated adults with sALCL or other CD30-positive PTCL, including AITL and PTCL-NOS.

    Source:

  • Oct 19, 2026, 09:30 UTC

    Takeda announced new VERDICT trial data showing that treating adults with ulcerative colitis with intravenous ENTYVIO to achieve corticosteroid-free disease clearance, rather than symptomatic remission alone, prolonged time to the first UC-related complication (hazard ratio 0.33; 95% confidence interval 0.17–0.67; P=0.0014).

    Source:

  • Oct 16, 2026, 14:00 UTC

    The UK High Court upheld Takeda’s supplementary protection certificate for lisdexamfetamine and rejected challenges by Aristo Pharma GmbH and STADA Arzneimittel AG.

    Source:

  • Oct 15, 2026, 22:15 UTC

    Takeda Pharmaceutical shares closed at 6,183 yen, up 294 yen.

    Source:

  • Oct 15, 2026, 00:30 UTC

    Takeda announced that ORZEYFUL (oveporexton) is now available in Japan and China for treating narcolepsy type 1.

    Source:

  • Sep 29, 2026, 11:25 UTC

    Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.

  • Sep 28, 2026, 23:59 UTC

    The National Comprehensive Cancer Network included brigatinib (Alunbrig) in its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers as a recommended treatment for NF2-related schwannomatosis.

    Source:

  • Sep 23, 2026, 17:45 UTC

    AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.

    Source:

  • Sep 23, 2026, 08:06 UTC

    Roche announced it will nominate Christophe Weber, former CEO of Takeda Pharmaceutical, for election to its board of directors at its March 2027 shareholders meeting.

    Source:

  • Sep 18, 2026, 11:30 UTC

    Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.

    Source:

  • Sep 18, 2026, 03:41 UTC

    Dr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.

    Source:

  • Sep 16, 2026, 09:33 UTC

    Takeda Pharmaceutical received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for Elahere, an antibody-drug conjugate for FRα-positive platinum-resistant recurrent ovarian cancer, the first such ADC approved in Japan for this indication.

    Source:

  • Sep 16, 2026, 00:46 UTC

    On September 15, US-listed ADRs of Japanese companies traded with a slight selling bias, with Chugai Pharmaceutical and Takeda Pharmaceutical among the decliners, while Chicago Nikkei 225 futures settled at 63,405 yen, 285 yen above the Osaka daytime level.

    Source:

  • Sep 14, 2026, 07:00 UTC

    The U.S. FDA accepted Takeda's New Drug Application under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis.

    Source:

  • Sep 10, 2026, 21:45 UTC

    Former Takeda Pharmaceutical president and chairman Shigenori Hasegawa, who led the company's global expansion through large acquisitions, died.

    Source:

  • Sep 10, 2026, 09:34 UTC

    Takeda Pharmaceutical announced that Andy Plump, president of its research and development division, plans to retire effective June 2027.

    Source:

  • Sep 9, 2026, 13:00 UTC

    Rakuten Medical announced that Christophe Weber, former CEO of Takeda Pharmaceutical, has been appointed Vice Chairman of the Board, effective September 1, 2026.

    Source:
Page 1Next →